22

nanotimes

Companies

Facts

D. Pires, J. L. Hedrick, A. De Silva, J. Frommer, B. Gots- mann, H. Wolf, M. Despont, U. Duerig and A. W. Knoll: Nanoscale 3D Patterning of Molecular Resists by Scanning Probes, In: Science Express, April 22, 2010, DOI:10.1126/ science. 1187851:

http://dx.doi.org/10.1126/science. 1187851

A. Knoll, D. Pires, O. Coulembier, P. Dubois, J. L. Hedrick, J. Frommer and U. Duerig: Probe-based 3-D Nanolitho- graphy Using Self-Amplified Depolymerization Polymers; In: Advanced Materials AOP, April 23, 2010, DOI:10.1002/ adma. 200904386:

http://dx.doi.org/10.1002/adma.200904386 http://www.ibm.com

I

llumina, Inc. (NASDAQ: ILMN) announced the launch of its VeraCode ADME Core Panel designed

to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most comple- te representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List. The panel contains 184 biomarkers in 34 genes, with the highest coverage of the PharmADME Core List. Using a highly specific and streamlined chemistry, DNA can be genotyped within 8 hours with less than 2.5 hours of hands-on time, enabling researchers to complete studies faster than ever before.

Furthermore, the Company announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for the company‘s BeadX- press system for multiplex genetic analysis. Accor- ding to the FDA‘s indications of use, the BeadXpress system – consisting of Illumina‘s BeadXpress Reader

Advertisement

10-04 :: April 2010